预约演示
Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia
引进/卖出上市批准临床3期临床2期临床1期
The asset is currently being investigated as a potential treatment for metastatic pancreatic ductal adenocarcinoma. MattL_Images/Shutterstock.
Taiho Pharmaceutical has exercised an option for an exclusive licence tmetastatic pancreatic ductal adenocarcinomaes’ quemliclustat (AB680) in Japan and Asian territories, excluding mainland China.
Taiho Pharmaceuticalime Taiho has opted into an Arcus programme under the ongoing collaboration betArcus BiosciencesanquemliclustatanAB680017.
Taiho will make an optioTaihorcise payment.
Taihoional milestones payments are contingent on meeting clinical, regulatory and commercial goals.
Taiho will also pay royalties on net sales if the product is approved.
Taiholso:Hong Kong approves Leqembi for Alzheimer’s treatment
Rgenta Therapeutics’ RGT-611Leqembis IND approval to treat cancers
An investigational small molecule CD73 inhibitor, quemliclustat is being investigated as a potential treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).
Rgenta TherapeuticschRGT-61159al, registrational Phase III cancersRISM-1 in 2024, which will assess quemliclustat plus chemotherapy against chemotherapy alone in previously untreated mPDAC patients.
The decision to progress to Phase III trials stems from promising overall survival results from the Phase Ib ARC-8 study.
With this licensing agreement, TaiCD73 inhibitorCD73ill support quemliclustatnt and potential commercialisation of quemliclustat metastatic pancreatic ductal adenocarcinoma (mPDAC) PRISM-1 study in Japan.
Arcus has already secured exclusive development and commercialisation rights for four Arcus programmquemliclustatnd Asian regions excluding mainland China.mPDAC
These include the CD73 inhibitor programme (quemliclustat), the dual A2a/b adenosine receptor antagonist programme (etrumadenant), the anti-PD-1 programme (zimberelimab), and the anti-TIGIT programme (domvanalimab and AB308).
Gilead Sciences holds the rightTaihocommercialise quemliclustat in the US and co-promote with Arcus, quemliclustatclusive rights to develop and commercialise the product outside the US.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。